A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA-1

Recruiting
100 years or below
Transgender
Phase N/A
1 Location

Brief description of study

d

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: all
  • Age: 100 years or below
  • Gender: Transgender

Inclusion Criteria:
Exclusion Criteria:

Updated on 21 Nov 2025. Study ID:

Find a site

Since this trial requires contact information verification, you will receive an email with the information you provided asking for your validation. Only after this verification step your referral will be sent to the study site selected.

To verify your phone, please use one of the verification methods below:

Send text message Send automated call

You have contacted ,

,

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team